Adaptive Biotechnologies Corporation ADPT | NASDAQ
|2026-10-06
Company Overview:
7.4 Year ADPT Performance Metrics:
Build Custom Charts
ADPT Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for ADPT
Based on past 7.4-year performance, here are ADPT growth metrics:
Share price CAGR of -4.33%
Dividend CAGR of +0%
Using ADPT CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| ADPT (DRIP) | ADPT - No DRIP | |
|---|---|---|
| Current Price | $29.04 | $29.04 |
| Start Shares | 344.35 | 344.35 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 344.35 | 344.35 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $18.65 | $29.04 |
| Total Dividends | $0 | $0 |
| Final Value | $6,422 | $10,000 |
NOTE: Above numbers are our estimate based on ADPT's Dividend and Price CAGR over past 7.4 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Adaptive Biotechnologies Corporation (ADPT) had its IPO on 2019-06-27, and is traded on NASDAQ stock exchange.
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.
ADPT website: https://www.adaptivebiotech.com
DCF Model — ADPT
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
